Myriam Curet

October 14, 2026

No recent news for STXS. There are no new developments for Stereotaxis Inc. in the past week. The company continues to trade near its 12‑month low, with an RSI of 22.8 indicating oversold conditions. The 52‑week range remains $1.09 to $3.59, and analysts maintain a target of $3.00.

October 14, 2026

Barclays Starts Coverage of Inspire Medical with Underweight. Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.

October 17, 2026

Intuitive Surgical Prepares for Q3 Earnings Amid Growth and Competition. Intuitive Surgical is approaching its Q3 earnings release, with analysts noting continued double‑digit revenue growth and expanding procedure volumes. At the same time, new robotic competitors are entering the market, prompting discussion of the company's current valuation multiples. The stock has shown strong price momentum, reflected in a relatively high RSI and recent touches near its 200‑day moving average.

October 16, 2026

NKTR receives mixed analyst coverage and pipeline focus. Several research firms started coverage on Nektar Therapeutics this week. UBS began coverage with a neutral rating and a $53 price target, while Leerink issued an outperform rating and set a $130 target, and Raymond James launched coverage with a market‑perform view. BTIG kept a buy rating with a $178 target. At the same time, commentary pieces note the company's pipeline progress and recent rezpegaldesleukin data, suggesting potential long‑term value and possible undervaluation.